APPENDIX A

1. U.S. Patent Application Publication No. 2005-0049294, Palladino et al., entitled METHODS OF USING (3.2.0) HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF, published on March 3, 2005.

2. U.S. Patent Application Publication No. 2009-0036390, Anderson et al., entitled COMPOSITIONS AND METHODS FOR TREATING NEOPLASTIC DISEASES, published on February 5, 2009.

3. U.S. Patent Application Publication No. 2009-0148445, Bonavida et al., entitled METHODS OF SENSITIZING CANCER TO THERAPY INDUCED CYTOTOXICITY, published on June 11, 2009.

4. U.S. Patent Application Publication No. 2009-0156469, Ghobrial et al., entitled METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF IN TREATING WALDENSTROM'S MACROGLOBULINEMIA, published on June 18, 2009.

5. PCT Publication No. WO 2008/124699, Palladino et al., entitled A METHOD OF USING PROTEASOME INHIBITORS IN COMBINATION WITH HISTONE DEACETYLASE INHIBITORS TO TREAT CANCER, published on October 16, 2008.

6. U.S. Application No. 12/329518, Chen-Kiang et al., entitled TARGETING CDK4 AND CDK6 IN COMBINATION CANCER THERAPY, filed on December 5, 2008.

7. R. Andtbacka, S. Khanbolooki, L. Lashinger, S. Nawrocki, M. Pino, M. Lu, T. Kwan, V. Cryns, T. Arumugam, C. Logsdon, M. Palladino, and D. McConkey. "The Proteasome Inhibitor NPI-0052 Overcomes TRAIL resistance in human pancreatic cancer cells in vitro and in vivo." (unpublished manuscript).

8. D. Chauhan, L. Catley, G. Li, K. Podar, T. Hideshima, M. Velankar, C. Mitsiades, N. Mitsiades, H. Yasui, A. Letai, H. Ovaa, C. Berkers, B. Nicholson, T. Chao, S. Neuteboom, P. Richardson, M. Palladino, and K Anderson. "A Novel Orally Active Proteasome Inhibitor Induces Apoptosis in Multiple Myeloma Cells with Mechanisms Distinct from Bortezomib." Cancer Cell. 8:407-419 (2005).

9. A. Roccaro, X. Jia, A. Sacco, M. Melhem, A. Moreau, X Leleu, H. Ngo, J. Runels, A. Azab, F. Azab, N. Burwick, M. Farag, S. Treon, M. Palladino, T. Hideshima, D. Chauhan, K. Anderson, and I. Ghobrial. "Dual Targeting of the Proteasome Regulates Survival and Homing in Waldenstrom Macroglobulinemia." Blood. (March 2008).

10. J. Cusack, R. Liu, L. Xia, D. Ljungman, R. Bahjat, and M. Palladino. "Oral Proteasome Inhibitor (NPI-0052) Enhances Sensitivity to Combination Gemcitabine and Erbitux in a Pancreatic Cancer Xenograft Model." AACR. (2005).

11. E. Suzuki, A. Jazirehi, M. Palladino, and B. Bonavida. "Chemosensitization of Drug and Rituximab Resistant Daudi B-NHL Clones to Drug-induced Apoptosis by the Proteasome Inhibitor NPI-0052." ASH. (2005).

12. S. Khanbolooki, S. Pino, R. Andtbacka, T. Chao, S. Neuteboom, M. Palladino, and D. McConkey. "Novel NF-κB Inhibitors NPI-1342/NPI-1387 and Proteasome Inhibitor NPI-0052 Overcome Resistance of Pancreatic Carcinoma to rhTRAIL." AACR. (2006).

13. R. Andtbacka, S. Khanbolooki, M. Pino, K. Zhu, and D. McConkey. "The Proteasome Inhibitor NPI-0052 Sensitizes Pancreatic Cancer Cells to TRAIL In Vitro and In Vivo." AACR. (2006).

14. A. Barral, T. Chao, S. Kanabolooki, G. Deyanat-Yazdi, B. Nicholson, D. McConkey, M. Palladino, and S. Neuteboom. "The Proteasome Inhibitor NPI-0052 Reduces Tumor Growth and Overcomes Resistance of Prostate Cancer to rhTRAIL via Inhibition of the NF-kB _Pathway." AACR. (2007).

11341607
060111